{"id":"NCT01134042","sponsor":"GlaxoSmithKline","briefTitle":"Study HZA106829: Efficacy/Safety Study of Fluticasone Furoate/Vilanterol (GW642444) in Adult and Adolescent Asthmatics","officialTitle":"HZA106829: A Randomised, Double-blind, Parallel Group, Multicentre Study of Fluticasone Furoate/GW642444 Inhalation Powder, Fluticasone Furoate Inhalation Powder Alone, and Fluticasone Propionate Alone in the Treatment of Persistent Asthma in Adults and Adolescents","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-06","primaryCompletion":"2011-10","completion":"2011-10","firstPosted":"2010-05-31","resultsPosted":"2013-08-08","lastUpdate":"2017-01-11"},"enrollment":587,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Asthma"],"interventions":[{"type":"DRUG","name":"Fluticasone Furoate/Vilanterol Inhalation Powder","otherNames":[]},{"type":"DRUG","name":"Fluticasone Furoate Inhalation Powder","otherNames":[]},{"type":"DRUG","name":"Fluticasone Propionate Inhalation Powder","otherNames":[]},{"type":"OTHER","name":"Placebo Inhalation Powder 1","otherNames":[]},{"type":"OTHER","name":"Placebo Inhalation Powder 2","otherNames":[]}],"arms":[{"label":"Fluticasone Furoate/Vilanterol","type":"EXPERIMENTAL"},{"label":"Fluticasone Furoate","type":"ACTIVE_COMPARATOR"},{"label":"Fluticasone Propionate","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of the study is to compare the efficacy and safety of fluticasone furoate/vilanterol (GW642444) inhalation powder administered once daily each evening with fluticasone furoate inhalation powder administered alone once daily each evening in adolescent and adult subjects 12 years of age and older with persistent bronchial asthma over a 24-week period.","primaryOutcome":{"measure":"Change From Baseline in Clinic Visit Trough (Pre-bronchodilator and Pre-dose) Forced Expiratory Volume in One Second (FEV1) at the End of the 24-week Treatment Period","timeFrame":"Baseline and Week 24","effectByArm":[{"arm":"FF 200 µg OD","deltaMin":0.201,"sd":0.0303},{"arm":"FF/VI 200/25 µg OD","deltaMin":0.394,"sd":0.0302},{"arm":"FP 500 µg BID","deltaMin":0.183,"sd":0.03}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"},{"comp":"OG001 vs OG002","p":"<0.001"},{"comp":"OG000 vs OG002","p":null}]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":6},"locations":{"siteCount":71,"countries":["United States","Germany","Japan","Poland","Romania","Russia"]},"refs":{"pmids":["32771685","27881132","26704701","24136330"],"seeAlso":["https://www.clinicalstudydatarequest.com"]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":194},"commonTop":["Nasopharyngitis","Headache","Cough","Respiratory tract infection viral","Influenza"]}}